180 related articles for article (PubMed ID: 9517948)
1. Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept.
Firsov AA; Shevchenko AA; Vostrov SN; Zinner SH
Antimicrob Agents Chemother; 1998 Mar; 42(3):659-65. PubMed ID: 9517948
[TBL] [Abstract][Full Text] [Related]
2. MIC-based interspecies prediction of the antimicrobial effects of ciprofloxacin on bacteria of different susceptibilities in an in vitro dynamic model.
Firsov AA; Vostrov SN; Shevchenko AA; Zinner SH; Cornaglia G; Portnoy YA
Antimicrob Agents Chemother; 1998 Nov; 42(11):2848-52. PubMed ID: 9797214
[TBL] [Abstract][Full Text] [Related]
3. A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities.
Firsov AA; Vostrov SN; Shevchenko AA; Portnoy YA; Zinner SH
Antimicrob Agents Chemother; 1998 Nov; 42(11):2841-7. PubMed ID: 9797213
[TBL] [Abstract][Full Text] [Related]
4. Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model.
Firsov AA; Vostrov SN; Kononenko OV; Zinner SH; Portnoy YA
Antimicrob Agents Chemother; 1999 Mar; 43(3):498-502. PubMed ID: 10049257
[TBL] [Abstract][Full Text] [Related]
5. Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio.
Vostrov SN; Kononenko OV; Lubenko IY; Zinner SH; Firsov AA
Antimicrob Agents Chemother; 2000 Apr; 44(4):879-84. PubMed ID: 10722485
[TBL] [Abstract][Full Text] [Related]
6. Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model.
Firsov AA; Vasilov RG; Vostrov SN; Kononenko OV; Lubenko IY; Zinner SH
J Antimicrob Chemother; 1999 Apr; 43(4):483-90. PubMed ID: 10350376
[TBL] [Abstract][Full Text] [Related]
7. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
Zinner SH; Vostrov SN; Alferova IV; Lubenko IY; Portnoy YA; Firsov AA
Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
[TBL] [Abstract][Full Text] [Related]
8. Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses.
Firsov AA; Lubenko IY; Vostrov SN; Kononenko OV; Zinner SH; Portnoy YA
J Antimicrob Chemother; 2000 Nov; 46(5):725-32. PubMed ID: 11062191
[TBL] [Abstract][Full Text] [Related]
9. Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and doses.
Firsov AA; Zinner SH; Lubenko IYu ; Vostrov SN
Int J Antimicrob Agents; 2000 Dec; 16(4):407-14. PubMed ID: 11118849
[TBL] [Abstract][Full Text] [Related]
10. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model.
Firsov AA; Vostrov SN; Shevchenko AA; Cornaglia G
Antimicrob Agents Chemother; 1997 Jun; 41(6):1281-7. PubMed ID: 9174184
[TBL] [Abstract][Full Text] [Related]
11. Bacterial strain-independent AUC/MIC and strain-specific dose-response relationships reflecting comparative fluoroquinolone anti-pseudomonal pharmacodynamics in an in vitro dynamic model.
Lubenko IY; Vostrov SN; Portnoy YA; Zinner SH; Firsov AA
Int J Antimicrob Agents; 2002 Jul; 20(1):44-9. PubMed ID: 12127710
[TBL] [Abstract][Full Text] [Related]
12. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model.
Madaras-Kelly KJ; Ostergaard BE; Hovde LB; Rotschafer JC
Antimicrob Agents Chemother; 1996 Mar; 40(3):627-32. PubMed ID: 8851583
[TBL] [Abstract][Full Text] [Related]
13. Antistaphylococcal effect related to the area under the curve/MIC ratio in an in vitro dynamic model: predicted breakpoints versus clinically achievable values for seven fluoroquinolones.
Firsov AA; Lubenko IY; Vostrov SN; Portnoy YA; Zinner SH
Antimicrob Agents Chemother; 2005 Jul; 49(7):2642-7. PubMed ID: 15980331
[TBL] [Abstract][Full Text] [Related]
14. Comparative anti-staphylococcal effects of gemifloxacin and trovafloxacin in an in vitro dynamic model in terms of AUC/MIC and dose relationships.
Zinner SH; Vostrov SN; Lubenko IY; Portnoy YA; Cornaglia G; Firsov AA
Diagn Microbiol Infect Dis; 2001 Aug; 40(4):167-71. PubMed ID: 11576789
[TBL] [Abstract][Full Text] [Related]
15. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus.
Firsov AA; Vostrov SN; Lubenko IY; Drlica K; Portnoy YA; Zinner SH
Antimicrob Agents Chemother; 2003 May; 47(5):1604-13. PubMed ID: 12709329
[TBL] [Abstract][Full Text] [Related]
16. Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters.
Firsov AA; Zinner SH; Lubenko IY; Portnoy YA; Vostrov SN
Chemotherapy; 2002; 48(6):275-9. PubMed ID: 12673102
[TBL] [Abstract][Full Text] [Related]
17. AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin.
Firsov AA; Zinner SH; Vostrov SN; Portnoy YA; Lubenko IY
J Antimicrob Chemother; 2002 Oct; 50(4):533-9. PubMed ID: 12356798
[TBL] [Abstract][Full Text] [Related]
18. Enrichment of fluoroquinolone-resistant Staphylococcus aureus: oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window.
Firsov AA; Lubenko IY; Smirnova MV; Strukova EN; Zinner SH
Antimicrob Agents Chemother; 2008 Jun; 52(6):1924-8. PubMed ID: 18378704
[TBL] [Abstract][Full Text] [Related]
19. The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial susceptibility.
MacGowan AP; Wootton M; Holt HA
J Antimicrob Chemother; 1999 Mar; 43(3):345-9. PubMed ID: 10223589
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
Odenholt I; Cars O
J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]